Association between APOE polymorphisms and lipid profile in Mexican Amerindian population
Por:
Martínez-Magaña J.J., Genis-Mendoza A.D., Tovilla-Zarate C.A., González-Castro T.B., Juárez-Rojop I.E., Hernández-Díaz Y., Martinez-Hernandez A.G., Garcia-Ortíz H., Orozco L., López-Narvaez M.L., Nicolini H.
Publicada:
1 ene 2019
Resumen:
Background: Apolipoprotein E (ApoE) is a glycoprotein that plays an important role in lipid homeostasis at both cerebral and systemic levels. Moreover, the differential distribution of APOE gene alleles among different populations, means that ApoE isoforms could have different effects on lipids metabolism. The present study aims to evaluate the relationship between APOE gene alleles and the lipid profile in a Mexican Amerindian (MA) population. Methods: This study included 1997 MA individuals of different ethnicities distributed throughout different states of Mexico. All individuals underwent anthropometric measurements as well as laboratory tests including fasting glucose (FG), total cholesterol (TC), triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). TaqMan® probe genotyping assays were used to genotype APOE. The Kruskal–Wallis test was performed to determine the correlation between APOE gene alleles and genotypes and the biochemical variables measured. Results: Among the biochemical variables analyzed, only the HDL-C and LDL-C levels showed statistical differences (p-value <.05) between individuals carrying different APOE alleles. For HDL-C, individuals carrying the E2 allele had higher HDL-C levels, followed by individuals carrying the E3 allele and carriers of the E4 allele presented the lowest levels of HDL-C (E2 > E3 > E4). This relationship was inversed for LDL-C levels (E2 < E3 < E4). Nevertheless, the difference of HDL-C levels between APOE-E3 and APOE-E4 carriers remained only in obese individuals. Conclusions: Our results suggest that APOE gene genotypes play an important role in the differential modulation of lipid profiles in the MA population with obesity. © 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Filiaciones:
Martínez-Magaña J.J.:
National Institute of Genomic Medicine (Instituto Nacional de Medicina Genómica INMEGEN), Laboratory of Genomics of Psychiatric Diseases, Neurodegenerative and Addictions, Ministry of Health, Mexico City, Mexico
Genis-Mendoza A.D.:
National Institute of Genomic Medicine (Instituto Nacional de Medicina Genómica INMEGEN), Laboratory of Genomics of Psychiatric Diseases, Neurodegenerative and Addictions, Ministry of Health, Mexico City, Mexico
Tovilla-Zarate C.A.:
Comalcalco Multidisciplinary Academic Division, Autonomous Juárez University of Tabasco (Universidad Juárez Autónoma de Tabasco), Comalcalco, Tabasco, Mexico
González-Castro T.B.:
Multidisciplinary Academic Division of Jalpa de Méndez, Autonomous Juárez University of Tabasco (Universidad Juárez Autónoma de Tabasco), Jalpa de Méndez, Tabasco, Mexico
Juárez-Rojop I.E.:
Academic Division of Health Sciences, Autonomous Juárez University of Tabasco (Universidad Juárez Autónoma de Tabasco), Villahermosa, Tabasco, Mexico
Hernández-Díaz Y.:
Multidisciplinary Academic Division of Jalpa de Méndez, Autonomous Juárez University of Tabasco (Universidad Juárez Autónoma de Tabasco), Jalpa de Méndez, Tabasco, Mexico
Martinez-Hernandez A.G.:
National Institute of Genomic Medicine (INMEGEN), Laboratory of Immunogenomics and Metabolic Diseases, Ministry of Health, Mexico City, Mexico
Garcia-Ortíz H.:
National Institute of Genomic Medicine (INMEGEN), Laboratory of Immunogenomics and Metabolic Diseases, Ministry of Health, Mexico City, Mexico
Orozco L.:
National Institute of Genomic Medicine (INMEGEN), Laboratory of Immunogenomics and Metabolic Diseases, Ministry of Health, Mexico City, Mexico
López-Narvaez M.L.:
General Hospital of Yajalon, Ministry of Health, Yajalon, Chiapas, Mexico
Nicolini H.:
National Institute of Genomic Medicine (Instituto Nacional de Medicina Genómica INMEGEN), Laboratory of Genomics of Psychiatric Diseases, Neurodegenerative and Addictions, Ministry of Health, Mexico City, Mexico
|